Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study

<p>Abstract</p> <p>Background</p> <p>The aim of this study was to investigate the incidence and prognostic value of disseminated tumor cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to lymph node involvement...

Full description

Bibliographic Details
Main Authors: Gubern Josep M, Mariscal Antonio, Rull Miquel, Julian Juan F, Castellá Eva, Margelí Mireia, Solá Montserrat, Barnadas Agustí, Fraile Manuel
Format: Article
Language:English
Published: BMC 2011-06-01
Series:BMC Cancer
Subjects:
Online Access:http://www.biomedcentral.com/1471-2407/11/252
_version_ 1828259303237091328
author Gubern Josep M
Mariscal Antonio
Rull Miquel
Julian Juan F
Castellá Eva
Margelí Mireia
Solá Montserrat
Barnadas Agustí
Fraile Manuel
author_facet Gubern Josep M
Mariscal Antonio
Rull Miquel
Julian Juan F
Castellá Eva
Margelí Mireia
Solá Montserrat
Barnadas Agustí
Fraile Manuel
author_sort Gubern Josep M
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>The aim of this study was to investigate the incidence and prognostic value of disseminated tumor cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to lymph node involvement, determined by sentinel lymph node (SLN) biopsy analysis, and to prognostic factors of interest.</p> <p>Methods</p> <p>104 patients with operable (T < 3 cm) breast cancer and clinically- and sonographically-negative axillary lymph nodes were scheduled for SLN biopsy. Bone marrow aspirates were collected before the start of surgery from both iliac crests, and mononuclear cell layers were separated by density centrifugation (Lymphoprep). Slide preparations were then examined for the presence of disseminated tumor cells by immunocytochemistry with anti-cytokeratin antibodies (A45-B/B3). Lymphoscintigraphy was performed 2 hours after intratumor administration of 2 mCi (74 MBq) of 99mTc colloidal albumin. The SLN was evaluated for the presence of tumor cells by hematoxylin-eosin staining and, when negative, by immunocytochemistry using anti-cytokeratin antibody (CAM 5.2). Survival analyses and comparative analyses were performed on the results of bone marrow determinations, SLN biopsy, and known prognostic factors, including breast cancer subtypes according to the simplified classification based on ER, PR and HER2.</p> <p>Results</p> <p>Lymph node and hematogenous dissemination occur in one-third of patients with early-stage breast cancer, although not necessarily simultaneously. In our study, disseminated tumor cells were identified in 22% of bone marrow aspirates, whereas 28% of patients had axillary lymph node involvement. Simultaneous lymph node and bone marrow involvement was found in only 5 patients (nonsignificant). In the survival study (60 months), a higher, although nonsignificant rate of disease-related events (13%) was seen in patients with disseminated tumor cells in bone marrow, and a significant association of events was documented with the known, more aggressive tumor subtypes: triple negative receptor status (21%) and positive ERBB2 status (29%).</p> <p>Conclusions</p> <p>Tumor cell detection in bone marrow can be considered a valid prognostic parameter in patients with early disease. However, the classic prognostic factors remain highly relevant, and the newer breast cancer subtypes are also useful for this purpose.</p>
first_indexed 2024-04-13T03:05:56Z
format Article
id doaj.art-dd4484cc906c44d7a55e2b369bac9c16
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-04-13T03:05:56Z
publishDate 2011-06-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-dd4484cc906c44d7a55e2b369bac9c162022-12-22T03:05:15ZengBMCBMC Cancer1471-24072011-06-0111125210.1186/1471-2407-11-252Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational studyGubern Josep MMariscal AntonioRull MiquelJulian Juan FCastellá EvaMargelí MireiaSolá MontserratBarnadas AgustíFraile Manuel<p>Abstract</p> <p>Background</p> <p>The aim of this study was to investigate the incidence and prognostic value of disseminated tumor cells in bone marrow of breast carcinoma patients with early disease, and to analyze this finding in relation to lymph node involvement, determined by sentinel lymph node (SLN) biopsy analysis, and to prognostic factors of interest.</p> <p>Methods</p> <p>104 patients with operable (T < 3 cm) breast cancer and clinically- and sonographically-negative axillary lymph nodes were scheduled for SLN biopsy. Bone marrow aspirates were collected before the start of surgery from both iliac crests, and mononuclear cell layers were separated by density centrifugation (Lymphoprep). Slide preparations were then examined for the presence of disseminated tumor cells by immunocytochemistry with anti-cytokeratin antibodies (A45-B/B3). Lymphoscintigraphy was performed 2 hours after intratumor administration of 2 mCi (74 MBq) of 99mTc colloidal albumin. The SLN was evaluated for the presence of tumor cells by hematoxylin-eosin staining and, when negative, by immunocytochemistry using anti-cytokeratin antibody (CAM 5.2). Survival analyses and comparative analyses were performed on the results of bone marrow determinations, SLN biopsy, and known prognostic factors, including breast cancer subtypes according to the simplified classification based on ER, PR and HER2.</p> <p>Results</p> <p>Lymph node and hematogenous dissemination occur in one-third of patients with early-stage breast cancer, although not necessarily simultaneously. In our study, disseminated tumor cells were identified in 22% of bone marrow aspirates, whereas 28% of patients had axillary lymph node involvement. Simultaneous lymph node and bone marrow involvement was found in only 5 patients (nonsignificant). In the survival study (60 months), a higher, although nonsignificant rate of disease-related events (13%) was seen in patients with disseminated tumor cells in bone marrow, and a significant association of events was documented with the known, more aggressive tumor subtypes: triple negative receptor status (21%) and positive ERBB2 status (29%).</p> <p>Conclusions</p> <p>Tumor cell detection in bone marrow can be considered a valid prognostic parameter in patients with early disease. However, the classic prognostic factors remain highly relevant, and the newer breast cancer subtypes are also useful for this purpose.</p>http://www.biomedcentral.com/1471-2407/11/252Breast cancerDisseminated tumor cellsBone marrowSentinel nodeSurvival
spellingShingle Gubern Josep M
Mariscal Antonio
Rull Miquel
Julian Juan F
Castellá Eva
Margelí Mireia
Solá Montserrat
Barnadas Agustí
Fraile Manuel
Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
BMC Cancer
Breast cancer
Disseminated tumor cells
Bone marrow
Sentinel node
Survival
title Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
title_full Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
title_fullStr Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
title_full_unstemmed Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
title_short Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
title_sort prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients a prospective observational study
topic Breast cancer
Disseminated tumor cells
Bone marrow
Sentinel node
Survival
url http://www.biomedcentral.com/1471-2407/11/252
work_keys_str_mv AT gubernjosepm prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT mariscalantonio prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT rullmiquel prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT julianjuanf prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT castellaeva prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT margelimireia prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT solamontserrat prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT barnadasagusti prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy
AT frailemanuel prognosticvalueofhematogenousdisseminationandbiologicalprofileofthetumorinearlybreastcancerpatientsaprospectiveobservationalstudy